SunMo demonstrated superior progression-free survival and overall response for mosunetuzumab plus polatuzumab vedotin versus ...
In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...
Personalized treatment strategies have significantly advanced the management of lung cancer brain metastases, improving patient outcomes. Integration of targeted therapies and immunotherapies offers ...
We retrospectively analyzed clinicopathologic data of 98 patients with MCL treated at our center in the past 10 years. STATA 13.0 was used for overall survival (OS) and event-free survival (EFS) ...
8don MSN
Incyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
By Christy Santhosh May 30 (Reuters) - Incyte's Monjuvi as part of a multi-drug regimen that includes a chemotherapy standard of care for an aggressive form of non-Hodgkin lymphoma reduced the risk of ...
Morning Overview on MSN
The FDA just cleared Beqalzi for mantle cell lymphoma — sonrotoclax becoming the latest targeted therapy for a relapsed blood cancer with few options
Adults with mantle cell lymphoma who have already failed two or more treatments, including a BTK inhibitor, now have a new ...
SALT LAKE CITY — The five-year survival rate for all cancers combined has reached a historic 70%, according to the latest American Cancer Society Cancer Statistics 2026 report, based on all people ...
Being diagnosed with a serious disease like Hodgkin lymphoma is a lot to digest. But once you’ve had time to process your diagnosis, talk will likely turn to the treatments for classic Hodgkin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results